Bleeding, rhabdomyolysis and serotonin — the clarithromycin interaction storm

Pharmacological mechanism. All three acute problems flow from a single mechanism: clarithromycin is a potent inhibitor of cytochrome P450 3A4, the enzyme that clears the more potent S-enantiomer of warfarin and the lipophilic statins simvastatin, lovastatin and atorvastatin.^[1][2] Within two to four days of starting the course, the S-warfarin and the simvastatin accumulate several-fold. The S-warfarin accumulation produces a supratherapeutic INR (9.4) and upper-gastrointestinal bleeding — the melaena, the haemoglobin of 62 and the shock. The simvastatin accumulation produces statin myopathy progressing to rhabdomyolysis — the diffuse muscle pain, the creatine kinase of 14 200, the acute kidney injury from myoglobin (creatinine 340 from a baseline of 80) and the hyperkalaemia and the metabolic acidosis. A secondary contribution to her neuromuscular and autonomic state comes from the additive serotonergic load of the clarithromycin course in a patient already taking sertraline; while the classic SSRI–tramadol interaction is better recognised, any increment to the serotonergic load can precipitate serotonin toxicity, diagnosed by the Hunter criteria (clonus — inducible, spontaneous or ocular — agitation, diaphoresis, tremor and hyperreflexia; hypertonicity and temperature >38 °C mark life-threatening toxicity).^[3][4] The single course of clarithromycin has, by one enzyme, generated bleeding, rhabdomyolysis and a serotonergic contribution in a single patient.

Immediate resuscitation (ABCDE in parallel). Airway and breathing — high-flow oxygen, large-bore intravenous access, continuous cardiac monitoring because the hyperkalaemia and the acidosis place her at risk of arrhythmia. Circulation — she is in haemorrhagic shock with an INR of 9.4: resuscitate the bleed with blood products per the local massive-transfusion protocol and reverse the anticoagulation immediately. Disability — correct the hyperkalaemia and the acidosis that are driving the cardiac risk. A venous gas shows potassium 5.9 and pH 7.24.^[2]

Definitive management of the anticoagulation. She has life-threatening bleeding on warfarin with a supratherapeutic INR. Recker: after clarithromycin, INR rose to 16.8; warfarin was withheld and vitamin K was given (20 mg IM in that 1997 case). Current ED reversal of life-threatening warfarin bleeding is prothrombin complex concentrate plus vitamin K, with FFP if PCC is unavailable — milligram and unit-per-kilogram recipes are not in Recker and are not restated here. Check the INR and stop clarithromycin.^[2]

Definitive management of the rhabdomyolysis and the hyperkalaemia. Stop the simvastatin and the clarithromycin. Christensen: clarithromycin is expected to increase simvastatin/lovastatin AUC >5-fold; 14 of 16 statin–clarithromycin ADRs were rhabdomyolysis, all on a CYP3A4-metabolised statin. Give intravenous fluid for rhabdomyolysis-associated AKI (rate recipes are not in Christensen). Treat hyperkalaemia along usual membrane-stabilisation and intracellular-shift lines; milligram calcium/insulin/bicarbonate recipes are not in Christensen. Arrange early nephrology review. There is no role for activated charcoal (the antibiotic was started four days ago); the treatment is withdrawal of the precipitant, fluid, electrolyte control and renal support.^[1]

Disposition. Critical-care or high-dependency admission for the combination of haemorrhagic shock, an INR of 9.4 reversed under monitoring, rhabdomyolysis with acute kidney injury and hyperkalaemia, and the risk of arrhythmia and of needing renal replacement therapy. Stop the warfarin, the simvastatin and the clarithromycin; hold the sertraline only if the Hunter criteria are met on examination. Plan anticoagulation restart with the haematology team once the bleed is controlled, recognising that an alternative anticoagulant or a lower-intensity regimen may be appropriate. A medication review with the general practitioner at discharge.^[1]

Safe-prescribing decisions at the next pneumonia encounter — preventing recurrence. The single principle is that every new prescription interacts with the existing list, and the emergency physician checks the list and the organ function before writing. Concretely: in a patient on warfarin, a statin and an SSRI, avoid clarithromycin and erythromycin; substitute azithromycin (a macrolide that does NOT meaningfully inhibit CYP3A4), or step up to a respiratory fluoroquinolone or a beta-lactam as the syndrome requires. Hold the statin for the duration of any macrolide course if one cannot be avoided. Check the INR within two to four days of starting any interacting antibiotic and counsel the patient on bleeding signs. Reconcile the medication list at every encounter, check the renal function before any renally-cleared drug, and confirm the indication for each ongoing drug. The candidate who articulates the unifying CYP3A4 mechanism answers this from principle rather than from memory.^[1][2]